Page 24 - Outlayer Item News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nephrology News and Issues | For the first time in 2 years, the National Kidney Foundation Spring Clinical Meetings will take place live, organizers report. Tara I. Chang, MD, MS, said attendees are looking forward to the change.“I think many people are ready; we all miss that in-person interaction,” Chang, the 2022 Spring Clinical Meetings (SCM22) conference chair and division chief and associate professor of

Prescriptions dispensed for apixaban beyond 90 days after hospitalization resulted in a lower rate of hospitalization for recurrent venous thromboembolism compared with warfarin beyond 90 days, according to study results published in JAMA. However, researchers observed no significant differences in risk for hospitalization for major bleeds and no significant differences for comparisons between

The FDA granted orphan drug designation to NTLA-5001 for treatment of adults with relapsed or refractory acute myeloid leukemia. NTLA-5001 (Intellia Therapeutics) is an autologous T-cell receptor (TCR)-engineered T-cell therapy. The agent uses ex vivo CRISPR gene editing to insert a TCR on a patient’s T cells that targets the Wilms’ tumor 1 (WT1) antigen within and on the surface

NEW ORLEANS — Low-dose naltrexone decreased ocular pain and improved quality of life in patients with neuropathic corneal pain, according to Pam Theriot, OD, of Blink Eye Spa, who evaluated recent dry eye clinical research at SECO 2022.

In patients with rheumatoid arthritis initiating either TNF inhibitors or non-TNF inhibitor biologic therapies, severe obesity and low BMI each impeded treatment response, according to data published in Arthritis Care & Research.The researchers additionally found the efficacy of TNF inhibitor and non-TNF inhibitor therapies to be statistically similar across the range of body mass.